The analysis aimed to (a) describe the expression of IGF-1 and IGF-1R among different cancer types; (b) assess the prognostic values of IGF-1 and IGF-1R among varied tumors; and (c) evaluate the associations between IGF-1/IGF-1R and tumor immunity features including intratumoral immune infiltrates, checkpoint markers, tumor mutation burden (TMB), and microsatellite instability (MSI), which have been identified as biomarkers for predicting response to immune checkpoint inhibitor treatment (10). This evidence concerns the gene IGF1R and cancer.